Skip to content

10x Genomics

US · TXG #1311 by market cap Listed 2019
51.80 -5.58 -9.72%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 9.13 Expensive vs history 87th percentile
5-year average 5.84 · #110 of 126 in Medical Devices
P/E ratio -111.90 Cheap vs history 12th percentile
5-year average -43.99 · forward -82.26
P/S ratio 12.37 Expensive vs history 84th percentile
5-year average 8.42 · forward 11.05 · #120 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
10x Genomics (TXG) 6.81B -99.62 8.13 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value40.50 Economic moatNone UncertaintyVery High

Trading 21.8% above Morningstar's fair value estimate.

Fair value

10x Genomics Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 44% premium over our quantitative fair value estimate of $40.50 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The firm's lack of profitability undermines our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 90.2, which sits in the top 10% compared with peers globally. This suggests limited cash flow is available for reinvestment or return to shareholders, which contributes to our view that shares are overvalued.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 10.8%, a core component of valuation, sits in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

10x Genomics discussion 0 comments

Add a comment